Blood Group Typing Market Size

Global Blood Group Typing Market size was valued at USD 1.89 Billion in 2023 and is poised to grow from USD 2.08 Billion in 2024 to USD 4.18 Billion by 2032, growing at a CAGR of 9.1% during the forecast period (2025-2032).

Advancements in blood typing technologies, high demand for blood transfusions, launch of initiatives to promote awareness, high incidence of chronic diseases, and expansion of healthcare facilities are augmenting the adoption of blood group typing on a global level.

The growing incidence of chronic diseases, such as cancer and anemia, which often require blood transfusions, is driving the demand for blood group typing. Surging demand for blood transfusions and organ transplantations is a leading factor propelling the blood group typing market growth. Innovations such as polymerase chain reaction (PCR)-based techniques, microarray, and massively parallel sequencing have revolutionized the accuracy and efficiency of blood typing. The rapid expansion of hospitals, clinics, and diagnostic centers in both developed and developing regions is creating a robust demand for blood typing services. The integration of artificial intelligence (AI) and automation in blood typing processes is enhancing the accuracy and speed of diagnostics.

On the contrary, high costs of advanced blood group typing technologies, lack of infrastructure and trained professionals, variability in test results, and ethical and cultural barriers are estimated to limit the global blood group typing market penetration through 2032 and beyond.

What is the Role of AI in Blood group typing?

The adoption of automation and artificial intelligence (AI) is revolutionizing blood group typing by enhancing accuracy, reducing manual errors, and improving efficiency. Automated platforms streamline sample processing, analysis, and reporting, allowing for high-throughput testing in hospital labs and blood banks. AI-powered systems can analyze complex serological data, flag discrepancies, and assist in decision-making. This trend is particularly strong in developed countries where clinical laboratories face pressure to deliver faster results with minimal human intervention. As demand for precision medicine grows, these intelligent systems are becoming critical to delivering safe, timely, and accurate blood compatibility assessments, thus shaping the market’s future.